Lv11
96 积分 2023-07-14 加入
A matching-adjusted indirect comparison of first-line lorlatinib and alectinib for the treatment of ALK-rearranged advanced non-small cell lung cancer
1小时前
待确认
Molecular mechanisms of acquired resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer
26天前
已完结
Unlocking the potential: tissue mutation abundance as a predictor for third-generation EGFR-TKI efficacy in NSCLC
26天前
已完结
Mutational landscape and tyrosine kinase inhibitor sensitivity in EGFR L833 and H835 mutated non–small cell lung cancer
26天前
已完结
Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments
2个月前
已完结
Are all the IL-23 blockers the same in inflammatory bowel disease?
2个月前
已完结
Long‐term follow‐up demonstrates curative potential of autologous stem cell transplantation for relapsed follicular lymphoma
5个月前
已完结
Outcomes of Autologous Haematopoietic Stem Cell Transplant in Lymphomas: A Single Centre Study
5个月前
已关闭
Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study
5个月前
已完结
Management of HER2 alterations in non-small cell lung cancer – The past, present, and future
5个月前
已完结
皖公网安备34019202002308
